JP2023554587A5 - - Google Patents
Info
- Publication number
- JP2023554587A5 JP2023554587A5 JP2023528270A JP2023528270A JP2023554587A5 JP 2023554587 A5 JP2023554587 A5 JP 2023554587A5 JP 2023528270 A JP2023528270 A JP 2023528270A JP 2023528270 A JP2023528270 A JP 2023528270A JP 2023554587 A5 JP2023554587 A5 JP 2023554587A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- fused
- antibody
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20306370.6 | 2020-11-12 | ||
| EP20306370 | 2020-11-12 | ||
| EP21305091 | 2021-01-26 | ||
| EP21305091.7 | 2021-01-26 | ||
| PCT/EP2021/081303 WO2022101302A1 (en) | 2020-11-12 | 2021-11-10 | Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023554587A JP2023554587A (ja) | 2023-12-28 |
| JP2023554587A5 true JP2023554587A5 (cg-RX-API-DMAC7.html) | 2024-09-09 |
Family
ID=78599029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023528270A Pending JP2023554587A (ja) | 2020-11-12 | 2021-11-10 | Ｓａｒｓ－ｃｏｖ－２ スパイクタンパク質の受容体結合ドメインにコンジュゲートまたは融合している抗体およびワクチン目的でのそれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240010739A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4244253A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023554587A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230107260A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3200878A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2023007284A2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023005570A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022101302A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU20210070A7 (es) * | 2021-08-20 | 2023-03-07 | Ct Ingenieria Genetica Biotecnologia | Antígenos quiméricos para el control de coronavirus y composiciones que los comprenden |
| US20260034207A1 (en) * | 2022-06-30 | 2026-02-05 | Eps Innovative Medicine (Japan) Co., Ltd. | Vaccine composition for sublingual administration |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| DE69434860T2 (de) | 1993-02-22 | 2007-03-15 | The Rockefeller University | Herstellung von helfer-freien retroviren mit hohem titer mittels transienter transfektion |
| FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
| IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| CN101657464A (zh) | 2007-02-02 | 2010-02-24 | 贝勒研究院 | 与靶向人源化单克隆抗体复合的多变量抗原 |
| CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| ES2685823T3 (es) | 2008-07-16 | 2018-10-11 | Baylor Research Institute | Anticuerpos antagonistas anti-CD40 |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| DK2406289T3 (en) | 2009-03-10 | 2017-05-01 | Baylor Res Inst | ANTIGEN PRESENTING CELL TARGETED ANTIVIRUS VACCINES |
| US8345509B2 (en) | 2009-04-16 | 2013-01-01 | Chevron U.S.A., Inc. | System and method to create three-dimensional images of non-linear acoustic properties in a region remote from a borehole |
| EP2477655A4 (en) | 2009-09-14 | 2014-02-12 | Baylor Res Inst | VACCINES TREATED ON LANGERHANS CELLS |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| KR20130108295A (ko) | 2010-08-13 | 2013-10-02 | 베일러 리서치 인스티튜트 | 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제 |
| CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| EA029661B1 (ru) | 2013-09-06 | 2018-04-30 | Ауриген Дискавери Текнолоджиз Лимитед | Производные 1,3,4-оксадиазола и 1,3,4-тиадиазола в качестве иммуномодуляторов |
| HUE038169T2 (hu) | 2013-09-06 | 2018-09-28 | Aurigene Discovery Tech Ltd | 1,2,4-Oxadiazol származékok mint immunomodulátorok |
| US10610585B2 (en) * | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
| CN111217917B (zh) * | 2020-02-26 | 2020-10-23 | 康希诺生物股份公司 | 一种新型冠状病毒SARS-CoV-2疫苗及其制备方法 |
| CN111533809A (zh) * | 2020-04-21 | 2020-08-14 | 中国科学院武汉病毒研究所 | 针对新型冠状病毒的亚单位疫苗及应用 |
-
2021
- 2021-11-10 MX MX2023005570A patent/MX2023005570A/es unknown
- 2021-11-10 JP JP2023528270A patent/JP2023554587A/ja active Pending
- 2021-11-10 EP EP21806276.8A patent/EP4244253A1/en active Pending
- 2021-11-10 CA CA3200878A patent/CA3200878A1/en active Pending
- 2021-11-10 US US18/036,237 patent/US20240010739A1/en active Pending
- 2021-11-10 KR KR1020237017668A patent/KR20230107260A/ko active Pending
- 2021-11-10 WO PCT/EP2021/081303 patent/WO2022101302A1/en not_active Ceased
-
2023
- 2023-06-01 CO CONC2023/0007284A patent/CO2023007284A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023528017A5 (cg-RX-API-DMAC7.html) | ||
| AU2004279877B2 (en) | Fully human antibodies against human 4-1BB (CD137) | |
| JP5363432B2 (ja) | 樹状細胞−ｔ細胞の相互作用を調節するための組成物及び方法 | |
| EP2406286B1 (en) | Anti-cd40 antibodies and uses thereof | |
| US7563445B2 (en) | CD40 binding molecules and CTL peptides for treating tumors | |
| CN105884903B (zh) | 靶向抗原呈递细胞的疫苗 | |
| EP1434596B1 (en) | Enhancement of immune responses by agonist 4-1bb-antibodies | |
| EP3138854B1 (en) | Antibodies against cd40 | |
| KR20130036246A (ko) | 사람 ｃｄ8+ ｔ 세포의 수지상 세포 면역수용체(ｄｃｉｒ)-매개 교차프라이밍 | |
| TW200902061A (en) | Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells | |
| CN113797332B (zh) | 用于免疫疗法的组合物和方法 | |
| EP1599504A1 (en) | Modified antibody | |
| KR20090114466A (ko) | 덱틴-1을 통한 사람 항원제시세포 활성화의 치료학적 적용 | |
| KR20090127886A (ko) | 수지상 세포 렉틴 유사 산화된 ｌｄｌ 수용체-1(ｌｏｘ-1)을 통한 사람 항원제시세포의 활성화 | |
| KR20090118981A (ko) | Ｃｌｅｃ-6을 통한 사람 항원제시세포의 활성화 | |
| CN1423700A (zh) | 含有针对nkg2d受体复合物的表位的结合位点的多功能多肽 | |
| JP2023554587A5 (cg-RX-API-DMAC7.html) | ||
| Tunheim et al. | Human receptors of innate immunity (CD14, TLR2) are promising targets for novel recombinant immunoglobulin-based vaccine candidates | |
| HK1153501A (en) | Agents that engage antigen - presenting cells through dendritic cell asialoglycoprotein receptor (dc-asgpr) | |
| HK1227905A1 (en) | Antigen presenting cell targeted vaccines | |
| HK1227905A (en) | Antigen presenting cell targeted vaccines | |
| HK1178546A (en) | Antigen presenting cell targeted vaccines |